Hairy cell leukemia durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients

Michael J. Magee, Susan McKenzie, Daniel A. Filippa, Zalmen A. Arlin, Timothy S. Gee, Bayard D. Clarkson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Twenty‐three of 26 patients with hairy cell leukemia evaluable for response to splenectomy had significant improvement in anemia, thrombocytopenia, and/or neutropenia. Eight of the 23 had a recurrence of cytopenia after a median response duration of 4 to 5 months (range, 1‐22). The remaining 15 patients did not have a recurrence of cytopenia at 20 months median follow‐up (range, 1‐76). Six patients with postsplenectomy cytopenia were given androgenic steroids. Two of the six had an improvement in anemia and thrombocytopenia, and a third patient had an improvement in neutropenia. It was concluded that, although most patients with hairy cell leukemia have initial improvement in cytopenia with splenectomy, a significant number of them either fail to respond or have recurrent cytopenia after initial response to splenectomy. A trial of androgenic steroids is a reasonable therapeutic option in these patients. Alternative therapies are reviewed and recommendations made.

Original languageEnglish
Pages (from-to)2557-2562
Number of pages6
JournalCancer
Volume56
Issue number11
DOIs
StatePublished - 1 Dec 1985
Externally publishedYes

Fingerprint

Dive into the research topics of 'Hairy cell leukemia durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients'. Together they form a unique fingerprint.

Cite this